Fecal Microbiota Transplant (FMT) AKA Microbiota Restoration Therapy, Research to Clinical Tuesday, April 7, 2015

Lee Jones, Founder, President and CEO of Rebiotix Inc, has over thirty years of experience in the medical technology industry in large and small companies and academia. Rebiotix is developing a new category of biologic drugs that use live human-derived organisms to treat disease. Lead candidate RBX2660 (microbiota suspension) is currently undergoing clinical study for recurrent C. diff. infection. Glenn Taylor is the Microbiologist at the Taymount Clinic just outside London in the UK. He has spent five years researching the commensal colonization of bacteria in the human digestive system. Listen in as both guests discuss the Fecal or Faecal Microbiota Transplant (FMT),also known as Microbiota Restoration Therapy to treat recurrent C. diff. infections and more – Research to Clinical Professor Sheridan, C. diff. Survivor and FMT Patient : Nancy Sheridan is a full time, Associate Professor at the Fashion Institute of Technology and a winner of the prestigious SUNY Chancellor’s Award for Excellence in Teaching. Professor Sheridan has been teaching since fall 2000 in the Fashion Merchandising Management Department within the School of Business and Technology. For the past seven years, she has also taught a Retail Merchandising course at the University of Pennsylvania, Wharton Business School to undergraduate and MBA students. In June of 2014, Nancy had surgery and contracted c.diff while in the hospital, suffered 5 c.diff reoccurrences from June to December 2014 in January she received a Fecal Microbiota Transplant and has been c diff free since.